Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Ali_Health
|
| gptkbp:acquisition |
CSPC Pharmaceutical Group acquired 100% of the shares of a company in 2018.
|
| gptkbp:awards |
Numerous industry awards
|
| gptkbp:capital |
Approximately 20 billion USD (2020)
|
| gptkbp:ceo |
gptkb:Liang_Jianzhang
|
| gptkbp:clinical_trial |
Conducts clinical research in various fields
Conducts clinical trials for new drugs Phase III clinical trials ongoing |
| gptkbp:collaborations |
Collaborates with universities and research institutions
Collaborates with global research organizations |
| gptkbp:community_engagement |
Engages in community health initiatives
|
| gptkbp:employees |
Over 20,000
|
| gptkbp:financial_performance |
Consistent growth in revenue
Publishes annual financial reports. |
| gptkbp:focus |
gptkb:Research_and_development
Manufacturing Sales and marketing |
| gptkbp:founded |
gptkb:1997
|
| gptkbp:global_presence |
Operates in over 30 countries
|
| gptkbp:headquarters |
Shijiazhuang, China
|
| https://www.w3.org/2000/01/rdf-schema#label |
CSPC Pharmaceutical Group
|
| gptkbp:invention |
Holds many patents for pharmaceutical products
|
| gptkbp:investment |
Maintains active investor relations
Invests heavily in R& D |
| gptkbp:language_of_instruction |
Diverse product pipeline
|
| gptkbp:market |
gptkb:China
International markets Regularly launches new products |
| gptkbp:marketing_strategy |
Focuses on innovation and quality
|
| gptkbp:partnership |
Various international pharmaceutical companies
|
| gptkbp:partnerships |
Partners with hospitals for clinical trials
|
| gptkbp:products |
Prescription drugs
Biopharmaceuticals Over-the-counter drugs |
| gptkbp:regulatory_compliance |
Obtains regulatory approvals for new drugs
|
| gptkbp:research_areas |
gptkb:healthcare_organization
Central nervous system Gastroenterology Immunology Pain management Endocrinology Cardiovascular Respiratory Anti-infectives Multiple research centers in China |
| gptkbp:revenue |
Approximately 3 billion USD (2020)
|
| gptkbp:social_responsibility |
Engages in CSR activities
|
| gptkbp:stock_exchange |
gptkb:Hong_Kong_Stock_Exchange
|
| gptkbp:subsidiary |
CSPC Ouyi Pharmaceutical
CSPC Weisheng Pharmaceutical CSPC Zhongqi Pharmaceutical Technology |
| gptkbp:supply_chain |
Robust supply chain management
|
| gptkbp:sustainability |
Focuses on sustainable practices
|
| gptkbp:training |
Provides extensive employee training programs
|
| gptkbp:website |
www.cspc.com.cn
|